glp-1 and insulin Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Agonists - What is
Description
Coverage Baseline Previously unavailable under Medicare Part D Only 13 states cover them in Medicaid (KFF HMA survey) 19% of large employers cover GLP-1s for obesity, though 43% of employers with 5,000+ employees offer coverage (KFF 2025 survey) Current Expansion ~50% of CVS Caremark clients now provide coverage for weight loss Medicare GLP-1 Bridge program launches coverage for eligible Medicare Part D patients 7/1/26 This aligns with a recent survey from Business Group on Health that found 67% of the surveyed employers now cover GLP-1s for weight loss (though a reduction is expected for 2027)
Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1
Guilt-free, hormone-friendly, and 100% delicious
In this week'sHomerun Slides, we continue with the 2015 ADA Guidelines with slides on: Correlation of A1c With Average Glucose, Management of
At the same time, our community publications are filled wit
Schedule a free GLP-1 consultation and save 20% off your first treatment.
